SXTP — 60 DEGREES PHARMACEUTICALS I
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| $906,610 | -3.9% | -$8.3M | — | -991.6% | -41.8% | -1096.4% | — | — | — | — |
Revenue YoY trend Net margin trend
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal quarter end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.78 | — | -0.67 | -0.89 | 2 | — |
| Mar 2027 | -0.90 | — | -0.90 | -0.90 | 1 | — |
| Jun 2027 | -0.88 | — | -0.88 | -0.88 | 1 | — |
| Sep 2027 | -0.91 | — | -0.91 | -0.91 | 1 | — |
| Dec 2027 | -0.89 | — | -0.89 | -0.89 | 1 | — |
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -3.31 | — | -3.16 | -3.45 | 2 | — |
| Dec 2027 | -2.14 | — | -0.70 | -3.58 | 2 | — |
| Dec 2028 | -0.60 | — | -0.60 | -0.60 | 1 | — |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-21 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 8 SEC-registered investment managers reported holding SXTP (60 DEGREES PHARMACEUTICALS I) in their latest 13F filings, with a combined reported value of $578.50K across 434.97K shares. That is +37.3% by share count (+118.14K shares) versus the previous quarter, while reported value moved +3.8%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 2 added to existing stakes, 1 trimmed, 3 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of 60 DEGREES PHARMACEUTICALS I (SXTP) include Kathmere Capital Management, LLC, ARMISTICE CAPITAL, LLC, Walleye Capital LLC, ranked by reported 13F value among the 28 institutional holders on this page.
SXTP is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 8 | 434.97K | $578.50K | +37.3% |
| Q2 2026 | 9 | 363.87K | $640.41K | +51.5% |
| Q1 2026 | 8 | 194.33K | $340.07K | +219.1% |
| Q4 2025 | 7 | 44.36K | $22.55K | +20.9% |
| Q3 2025 | 6 | 17.38K | $25.59K | +12.8% |
| Q2 2025 | 5 | 15.24K | $36.12K | -48.8% |
| Q1 2025 | 6 | 30.05K | $54.81K | -30.4% |
| Q4 2024 | 9 | 153.69K | $198.03K | +314.0% |
Over the 8 quarters shown, institutional share counts increased 183% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q4 2024 (+314.0%).
Top Institutional Holders (Q3 2026) — 8 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 390.95K | $519.97K | 0.03% | Add | |
| 14.55K | $19.35K | 0.00% | Hold | |
| 14.29K | $19.00K | 0.00% | Reduce | |
| 13.53K | $17.99K | 0.00% | Hold | |
| 1.48K | $1.96K | 0.00% | Add | |
| 84 | $110 | 0.00% | New | |
| 64 | $85 | 0.00% | New | |
| 25 | $33 | 0.00% | Hold |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 9 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 265.10K | $466.58K | 0.03% | Add | |
| 22.36K | $39.36K | 0.00% | New | |
| 17.64K | $31.05K | 0.00% | New | |
| 15.00K | $26.40K | 0.00% | New | |
| 14.55K | $25.61K | 0.00% | New | |
| 14.55K | $25.61K | 0.00% | Reduce | |
| 13.59K | $23.92K | 0.00% | Reduce | |
| 1.05K | $1.85K | 0.00% | Reduce | |
| 25 | $44 | 0.00% | Hold |
Q1 2026 — 8 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 144.68K | $253.19K | 0.02% | New | |
| 31.41K | $54.97K | 0.00% | Add | |
| 16.30K | $28.52K | 0.00% | Add | |
| 1.86K | $3.25K | 0.00% | Add | |
| 50 | $88 | 0.00% | New | |
| 25 | $43 | 0.00% | Reduce | |
| 8 | $14 | 0.00% | New | |
| 1 | $2 | 0.00% | New |
Q4 2025 — 7 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 22.05K | $11.21K | 0.00% | New | |
| 12.45K | $6.33K | 0.00% | Hold | |
| 6.74K | $3.42K | 0.00% | Add | |
| 1.51K | $769 | 0.00% | New | |
| 1.48K | $750 | 0.00% | Hold | |
| 100 | $51 | 0.00% | Hold | |
| 31 | $16 | 0.00% | Add |
Q3 2025 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 12.45K | $18.30K | 0.00% | Reduce | |
| 3.14K | $4.65K | 0.00% | Add | |
| 1.48K | $2.18K | 0.00% | Add | |
| 189 | $278 | 0.00% | New | |
| 100 | $141 | 0.00% | Hold | |
| 30 | $44 | 0.00% | Add |
Q2 2025 — 5 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 12.52K | $29.66K | 0.00% | Add | |
| 2.60K | $6.16K | 0.00% | Add | |
| 100 | $237 | 0.00% | Hold | |
| 14 | $33 | 0.00% | Reduce | |
| 13 | $30 | 0.00% | Add |
New Positions (Q3 2026)
- Robinhood Markets, Inc. 84 sh · $110
- Tower Research Capital LLC (TRC) 64 sh · $85
Fully Exited (vs previous quarter)
- XTX Topco Ltd sold 17.64K sh · $31.05K
- Kovack Advisors, Inc. sold 15.00K sh · $26.40K
- GEODE CAPITAL MANAGEMENT, LLC sold 14.55K sh · $25.61K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kathmere Capital Management, LLC | 390.95K | 265.10K | 144.68K | — | — | — | — | — | — | — | — | — | — |
| Geode Capital Management | 14.55K | 14.55K | 16.30K | 12.45K | 12.45K | 12.52K | 11.92K | — | — | 38.00K | — | — | — |
| Citadel Advisors | 14.29K | 22.36K | — | — | — | — | — | — | 10.10K | — | 100.63K | — | 22.19K |
| UBS Group AG | 13.53K | 13.59K | 31.41K | 1.48K | 1.48K | 14 | 16.19K | 20.41K | 3.31K | 34.48K | — | — | — |
| BARCLAYS PLC | 1.48K | 1.05K | 1.86K | 1.51K | — | — | — | — | — | — | — | — | — |
| Robinhood Markets, Inc. | 84 | — | — | — | — | — | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 64 | — | — | 6.74K | 3.14K | 2.60K | 1.55K | 3.73K | 1.47K | 7.09K | 6.92K | 3.08K | 3.00K |
| OSAIC HOLDINGS, INC. | 25 | 25 | 25 | 100 | 100 | 100 | 100 | 500 | — | — | — | — | — |
| CENTRAL BANK & TRUST CO | — | — | — | — | — | — | — | — | — | 167.00K | 268.00K | 357.00K | 468.00K |
| ARMISTICE CAPITAL, LLC | — | — | — | — | — | — | — | 98.93K | — | — | — | — | — |
| Walleye Capital LLC | — | — | — | — | — | — | — | — | — | — | — | 102.62K | 139.30K |
| XTX Topco Ltd | — | 17.64K | — | — | — | — | — | — | — | — | — | — | — |
| Kovack Advisors, Inc. | — | 15.00K | — | — | — | — | — | — | — | — | — | — | — |
| GEODE CAPITAL MANAGEMENT, LLC | — | 14.55K | — | — | — | — | — | — | — | — | — | — | — |
| TWO SIGMA SECURITIES, LLC | — | — | — | — | — | — | — | 15.44K | — | 17.20K | 24.19K | — | — |
| Virtu Financial LLC | — | — | — | — | — | — | — | — | 12.68K | 45.14K | 59.52K | — | 14.49K |
| HRT FINANCIAL LP | — | — | — | — | — | — | — | 12.59K | — | 28.79K | — | — | — |
| JANE STREET GROUP, LLC | — | — | — | 22.05K | — | — | — | — | — | — | — | — | — |
| NATIONAL BANK OF CANADA /FI/ | — | — | — | — | — | — | — | — | 4.00K | — | — | — | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | — | — | — | — | — | — | — | — | — | 13.30K | 13.54K | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold SXTP?
As of 2026-Q3, 8 institutional funds reported holding SXTP (60 DEGREES PHARMACEUTICALS I) in SEC 13F filings, with a combined reported value of $578.50K.
How many shares of SXTP do institutions own?
13F filers reported 434.97K shares of SXTP, worth $578.50K in aggregate at the end of 2026-Q3.
Is institutional ownership of SXTP rising or falling?
Share counts moved +37.3% versus the prior quarter — accumulation.
Who are the top institutional holders of SXTP?
The largest 13F holders are Kathmere Capital Management, LLC, ARMISTICE CAPITAL, LLC, Walleye Capital LLC, CENTRAL BANK & TRUST CO, XTX Topco Ltd; the top 25 are ranked at the top of this page.
Who are the major shareholders of 60 DEGREES PHARMACEUTICALS I?
The major shareholders of 60 DEGREES PHARMACEUTICALS I (SXTP) by reported 13F value are Kathmere Capital Management, LLC, ARMISTICE CAPITAL, LLC, Walleye Capital LLC, CENTRAL BANK & TRUST CO, XTX Topco Ltd, among 28 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.